Cytheris

Cytheris and CITN select recombinant interleukin-7 (CYT107) for studies

Tuesday, May 17, 2011

Cytheris, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, and the Cancer Immunotherapy Trials Network (CITN), a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center (COSC) headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, has selected recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

[Read More]

Cytheris announces publication of preclinical study

Tuesday, March 1, 2011

Cytheris, a clinical stage biopharmaceutical company focused on research and development of therapies for immune modulation, has announced publication of data showing IL-7 is able to overcome factors that thwart an effective immune response during chronic viremia in diseases such as HIV infection and viral hepatitis.

[Read More]